ArticleOpen forum infectious diseases2026
Risk of Hepatocellular Carcinoma or Hepatic Decompensation Associated With Steatotic Liver Disease in People With and Without HIV.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Steatotic liver disease (SLD) is highly prevalent in people with HIV (PWH), but factors influencing progression to hepatocellular carcinoma (HCC) and hepatic decompensation (HD) remain unclear. It is unknown if the risk of these outcomes associated with SLD differs by HIV status. Methods: Patients from the Veterans Aging Cohort Study-HIV (includes matched people without HIV [PWoH]) who underwent an ultrasound, computed tomography, or magnetic resonance imaging between 2001-2017 were included. Patients with diagnosed cirrhosis or chronic viral hepatitis were excluded. SLD was defined by a natural language processing algorithm; primary outcome of composite of HCC or HD was defined using International Classification of Diseases 9/10 codes and national cancer registry. Follow-up began on imaging study date and continued until incident HCC/HD, death, or 31 December 2024. Adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) of HCC/HD associated with SLD and HIV status were calculated. Results: Among 19 546 patients (mean age: 54 years; 96.6% male; 28.6% PWH), 13 617 (69.7%) had SLD identified by natural language processing. Rates of HCC/HD were lowest in PWoH and no SLD (18.0/10 000 person-years) and highest among PWH and SLD (46.8/10 000 person-years). When compared to PWoH without SLD, risk of HCC/HD was increased among PWH with SLD (aHR: 2.71; 95% CI: 2.10-3.49) and PWH without SLD (aHR: 1.62; 95% CI: 1.14-2.29), although no interaction between HIV and SLD was observed ( Conclusions: Among people without cirrhosis or chronic viral hepatitis, radiographic findings of SLD were associated with increased rates of HCC/HD, with the highest rate among PWH and SLD, independent of cardiometabolic factors, alcohol, and tobacco.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.